With three new and three recently repurposed drugs, treatment of multidrug-resistant tuberculosis (MDR-TB) is more hopeful today than at any time since it emerged in the 1980s and 1990s [1–3]. This optimism contrasts starkly with dismal global treatment success rates of 48–56% as reported by the World Health Organization (WHO) in its annual Global Tuberculosis Reports from 2014 to 2019 [4, 5]. In low- and middle-income countries, treatment of highly selected MDR-TB patients with a standardised 9–12 month regimen leads to 80% or better successful treatment outcomes http://bit.ly/384SFpY

中文翻译：

---

继续寻找治疗耐多药结核病的难以捉摸的标准短期方案

凭借三种新药和三种最近重新调整用途的药物，耐多药结核病 (MDR-TB) 的治疗比 1980 年代和 1990 年代出现以来的任何时候都更有希望 [1-3]。这种乐观情绪与世界卫生组织 (WHO) 在其 2014 年至 2019 年的年度全球结核病报告中报告的 48-56% 的惨淡全球治疗成功率形成鲜明对比 [4, 5]。在低收入和中等收入国家，使用标准化的 9-12 个月方案治疗高度选择的耐多药结核病患者可获得 80% 或更好的成功治疗结果 http://bit.ly/384SFpY